2008 Biosimilars Pharmaceutical Companies 
Express Pharma
SEPTEMBER 6, 2023
In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality generic medicines at capped prices for the general public. appeared first on Express Pharma.
PharmaState Academy
MAY 16, 2023
Over the next 15 to 20 years, you can expect pharma business models of today to be metamorphosed by biopharmaceuticals and biosimilars. 7) An analysis of ten pharmaceutical companies by Boston Consulting Group revealed the average production cost per pack was ca. $5 The value of Biologics (2008), pp. 60 for biologics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 23, 2008
The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. .
PharmaShots
MARCH 29, 2023
Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years.
PharmaShots
APRIL 13, 2023
model is a holistic approach to incorporate the same strategy to life science and pharmaceutical companies. A globally fast-growing, and largest pharmaceutical company in the world was created through a merger between Pfizer and Pharmacia. Model: Inspired by the industry 4.0 model, the pharma 4.0 over the previous year.
Expert insights. Personalized for you.
59 
Let's personalize your content